Fig. 8: MMV668754/Trifloxystrobin and Buparvaquone may have distinct target inhibition. | Communications Biology

Fig. 8: MMV668754/Trifloxystrobin and Buparvaquone may have distinct target inhibition.

From: Trifloxystrobin blocks the growth of Theileria parasites and is a promising drug to treat Buparvaquone resistance

Fig. 8

a Sequence alignment of parasite TaCytB protein sequences from TBL3 cells and Buparvaquone-resistant TBL3 cell lines. Positions of the mutations are highlighted in red. b Parasite load per infected host cell in Buparvaquone-resistant TBL3 cell line. Parasite number was evaluated after drug treatment (2 µM for 48 h) compared to DMSO (Ctrl) or Buparvaquone (Bup) treated cells. Host cells (at least n = 50) were assessed for each experiment and parasite nuclei (DAPI staining) per host cell were counted manually. These results are representative of three independent experiments. Kruskal Wallis non-parametric test followed by Dunn’s multiple comparison test. ****p < 0.0001.

Back to article page